Revenue
2018
2019
2020
2021
2022
2023
2024
2025
LEXICON PHARMACEUTICALS, INC. (LXRX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M | $6.0M | $1.1M | $0 | $0 | $23.4M | $32.3M | $26.6M | $15.9M | $0 | $130.0M | $22.9M | $2.2M | $1.1M | $1.8M | $4.9M | $10.7M |
| Research & development | $61.1M | $84.5M | $58.9M | $52.8M | $55.0M | $153.6M | $91.9M | $100.2M | $152.2M | $164.0M | $95.2M | $89.3M | $89.7M | $82.6M | $91.8M | $78.5M | $81.2M |
| Operating expenses | — | — | — | $100.9M | $87.4M | $204.4M | $180.6M | $166.5M | $222.3M | $206.4M | $128.5M | $123.2M | $104.6M | $109.5M | $115.9M | $100.6M | $100.7M |
| Operating income | −$48.9M | −$197.1M | −$171.8M | −$100.8M | −$87.1M | −$47.8M | $141.4M | −$103.3M | −$130.6M | −$127.2M | $1.5M | −$100.4M | −$102.4M | −$108.4M | −$114.1M | −$95.7M | −$90.0M |
| EBITDAderived | −$48.3M | −$196.6M | −$171.2M | −$100.3M | −$86.8M | −$44.9M | $145.1M | −$99.6M | −$127.2M | −$125.1M | $2.2M | −$98.4M | −$99.5M | −$104.2M | −$109.2M | −$90.3M | −$83.8M |
| Net income | −$50.3M | −$200.4M | −$177.1M | −$101.9M | −$87.8M | −$58.6M | $130.1M | −$120.5M | −$123.0M | −$131.4M | −$4.7M | −$100.3M | −$104.1M | −$110.2M | −$116.2M | −$101.8M | −$82.8M |
| Basic EPSper diluted share | -$0.14 | -$0.63 | -$0.80 | -$0.62 | -$0.60 | -$0.53 | $1.23 | -$1.14 | -$1.17 | -$1.27 | -$0.05 | -$1.31 | -$1.42 | -$0.23 | -$0.34 | -$0.34 | -$0.57 |
| Diluted EPSper diluted share | -$0.14 | -$0.63 | -$0.80 | -$0.62 | -$0.60 | -$0.53 | $1.16 | -$1.14 | -$1.17 | -$1.27 | -$0.05 | -$1.31 | -$1.42 | -$0.23 | -$0.34 | -$0.34 | -$0.57 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 25, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 2.0K | $1.49 | $3.0K | 1.91M |
| Feb 23, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 100.0K | $1.47 | $147.0K | 1.90M |
| Feb 20, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 100.0K | $1.48 | $148.0K | 1.80M |
| Feb 19, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 50.0K | $1.44 | $72.0K | 1.70M |
| Feb 18, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 133.7K | $1.32 | $176.5K | 1.65M |